Viatris Guides FY24 In Line With Estimates - Update

RTTNews | vor 616 Tagen
Viatris Guides FY24 In Line With Estimates - Update

(RTTNews) - While reporting financial results for the fourth quarter on Wednesday, healthcare company Viatris Inc. (VTRS) initiated its adjusted earnings and revenue guidance for the full-year 2024.

For fiscal 2024, the company now projects adjusted earnings in a range of $2.70 to $2.85 per share on total revenues between $15.25 billion and $15.75 billion.

On average, seven analysts polled by Thomson Reuters expect the company to report earnings of $2.81 per share on net sales of $15.30 billion for the year. Analysts' estimates typically exclude special items.

On Monday, the company announced that its Board of Directors approved a 2024 dividend policy of $0.48 per share and declared a quarterly dividend of $0.12 for each issued and outstanding share of the Company's common stock, payable on March 18, 2024, to shareholders of record at the close of business on March 11, 2024.

The Company also announced that its Board of Directors authorized a $1.0 billion increase to its share repurchase program and now authorizes the repurchase of up to $2.0 billion of the Company's shares of common stock.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
Viatris Announces US Commercial Launch Of RYZUMVl 0.75%

Viatris Announces US Commercial Launch Of RYZUMVl 0.75%

Healthcare company Viatris Inc. (VTRS) announced Monday the U.S. commercial launch of RYZUMVI (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the U.S.
RTTNews | vor 583 Tagen
Viatris Reaffirms FY22 Revenue Outlook, Declares Dividend - Update

Viatris Reaffirms FY22 Revenue Outlook, Declares Dividend - Update

While reporting financial results for the third quarter on Monday, healthcare company Viatris Inc. (VTRS) reaffirmed its total revenue guidance for the full-year 2022 to solid operating momentum despite foreign exchange headwinds and absorbing inflation impact to date.
RTTNews | vor 1094 Tagen
U.S. District Court Rules In Favor Of Merck In Patent Infringement Suit Against Viatris

U.S. District Court Rules In Favor Of Merck In Patent Infringement Suit Against Viatris

Merck (MRK), known as MSD outside of the United States and Canada, announced Thursday that the U.S. District Court for the Northern District of West Virginia ruled in favor of the company in a patent infringement suit against Viatris, Inc. (VTRS) related to sitagliptin, an active ingredient in JANUVIA, JANUMET and JANUMET XR.
RTTNews | vor 1140 Tagen
Wall Street May Open With Slightly Negative Bias

Wall Street May Open With Slightly Negative Bias

Slightly lower S&P and Nasdaq futures amid valuation concerns indicate a flat to negative start for stocks on Wall Street Wednesday morning. Data on manufacturing and services sector activity in the U.S. in the month of October may provide some direction to the mark
RTTNews | vor 1Std 4 Minuten